| Date | Title | | | 09/02/10 | Seattle Genetics Achieves Milestone under Antibody-Drug Conjugate
Collaboration with Agensys, an Affiliate of Astellas| BOTHELL, Wash., Sep 02, 2010 (BUSINESS WIRE) --Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it has
achieved a milestone under its antibody-drug conjugate (ADC)
collaboration with Agensys, Inc., an affiliate of Tokyo-based Astellas
Pharma Inc. The milestone was triggered by Agensys' initiation of a
phase I trial for AGS-16M8F, an ADC for the treatment of cancer
utilizing Seattle Genetics' technology.
"This trial initiation increases the t... |
|  | | 08/04/10 | Seattle Genetics to Present at the Canaccord Genuity 30th Annual Growth Conference| BOTHELL, Wash., Aug 04, 2010 (BUSINESS WIRE) -- Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that Eric L. Dobmeier, Chief Business Officer, will speak at the Canaccord Genuity 30th Annual Growth Conference on Tuesday, August 10, 2010, at 9:30 a.m. Eastern Time. A webcast of the presentation will be available from Seattle Genetics' website, http://www.seattlegenetics.com, under the "Investor and News" section.
About Seattle Genetics
Seattle Genetics is a clinical-stage biotechnology co... |
| | | 08/03/10 | Seattle Genetics Expands Antibody-Drug Conjugate Collaboration with Genentech| Seattle Genetics to Receive $12 Million Upfront Payment, Over $900 Million in Potential Fees and Milestone Payments and Mid-Single Digit Royalties
BOTHELL, Wash., Aug 03, 2010 (BUSINESS WIRE) -- Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that it has expanded its antibody-drug conjugate (ADC) collaboration agreement with Genentech, Inc., a member of the Roche Group (SWX:RO) (SWX:ROG) (Pink Sheets:RHHBY). Under the expanded agreement, Genentech will pay an upfront fee of $12 million f... |
| | | 07/27/10 | Seattle Genetics Reports Second Quarter 2010 Financial Results and Continued Pipeline Progress| Top-Line Data from Two Late-Stage Clinical Programs Anticipated During 2010; Strong Financial Position Driving Progress Across Broad Product Pipeline
Conference Call Today at 5:00 p.m. ET
BOTHELL, Wash., Jul 27, 2010 (BUSINESS WIRE) -- Seattle Genetics, Inc. (Nasdaq: SGEN) today reported financial results for the second quarter and six months ended June 30, 2010. The company also highlighted recent product development activities and upcoming milestones.
"We had a strong second quarter ... |
| | | 07/20/10 | Seattle Genetics and Agensys, an Affiliate of Astellas, Announce Initiation of Phase I Clinical Trial of ASG-5ME for Pancreatic Cancer| BOTHELL, Wash., Jul 20, 2010 (BUSINESS WIRE) -- Seattle Genetics, Inc. (Nasdaq:SGEN) and Agensys, Inc., an affiliate of Tokyo-based Astellas Pharma Inc., today announced that they have initiated a phase I clinical trial of ASG-5ME for the treatment of metastatic pancreatic cancer. ASG-5ME is an antibody-drug conjugate (ADC) that is being co-developed by both companies for the treatment of solid tumors.
"There is significant need for new pancreatic cancer therapies, demonstrated by the fact t... |
| |
|
